LinKinVax and Gustave Roussy Announced First Patient Dosed in Phase I/IIa Clinical Study on HPV.DCVax in HPV-positive Oropharyngeal Cancer
LinkinVAX Completes First Batch Production of “PanCov”, Its Next Generation Multi-variant Vaccine Against Covid and Other Coronaviruses
PARIS--(BUSINESS WIRE)--LinKinVax, a clinical-stage biotechnology company, announces the creation of its Scientific Advisory Board with the appointment of three experts in immunology and epidemiology.
LinKinVax Welcomes Interim Results of the ANRS VRI06 Phase I Trial Evaluating a Novel HIV Vaccine Candidate
LinKinVax and Gustave Roussy Collaborate on a Phase I/IIa HPV.DCVax Clinical Trial for the Treatment of Patients with HPV-Positive Oropharyngeal Cancer
LinKinVax Just Completed a New Round of Financing, Initiated in 2022, for a Total of €7,3 M
“We are delighted to welcome these four experts in healthcare product development. Their sound knowledge and extensive experience of the biopharmaceuticals industry will provide invaluable support for the various clinical stages of our drug candidates. We cannot wait to make vaccines available to as many people as possible, in particular the most advanced vaccines targeting HIV and Covid, which are real public health issues,” comments André-Jacques Auberton-Hervé, Chairman and Co-Founder of LinKinVax.